Letter to the editor: l‐ornithine l‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial
Alexander J. Kovalic, Tai‐Ping Lee, Ben L. Da – 4 July 2022
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease
Huapeng Lin, Terry Cheuk‐Fung Yip, Xinrong Zhang, Guanlin Li, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Jimmy Che‐To Lai, Stephen Lam Chan, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong – 4 July 2022
Letter to the editor: Six‐month antibody kinetics and durability in liver transplant recipients after two doses of SARS‐CoV‐2 mRNA vaccination
Amy Chang, Alexandra T. Strauss, Jennifer L. Alejo, Teresa P.‐Y. Chiang, Nicole F. Hernandez, Laura B. Zeiser, Brian J. Boyarsky, Robin K. Avery, Aaron A. R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik‐Wang, Allan B. Massie, William A. Werbel, Dorry L. Segev – 4 July 2022
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials
Jihyun An, Seungbong Han, Ha Il Kim, Ju Hyun Shim – 3 July 2022 – To date, no studies have compared the new first‐line atezolizumab+bevacizumab with transarterial therapies combined with the prior standard‐of‐care, sorafenib, in patients with advanced hepatocellular carcinoma (HCC). We compared and ranked all relevant transarterial and targeted treatments competing with atezolizumab+bevacizumab for such disease, based on direct and indirect evidence.
Reply
Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jérôme Boursier, Philippe Mathurin, Céline Ribet, Victor Ledinghen, Marie Zins, Marie‐Aline Charles – 2 July 2022
Letter to the editor: Risk factors of NAFLD in preterm and low birthweight. More questions than answers!
Nitisha Mondia, Satender Pal Singh, Ajay Kumar Mishra – 2 July 2022
Caring for a child after a liver transplant: Challenges beyond medical complexity
Adriana Perez, Nadia Ovchinsky – 1 July 2022
Annual Report and Financial Statements
AASLD’s mission is to advance and disseminate the science and practice of hepatology and to promote liver health and quality patient care. See how we have advanced our mission by viewing our recent annual reports.
The diagnosis and management of nonalcoholic fatty liver disease: A patient‐friendly summary of the 2018 AASLD guidelines
Connor Griffin, Ranjeeta Bahirwani – 30 June 2022